Condition
Immune Thrombocytopenia
Immune thrombocytopenia is a condition in which the immune system mistakenly attacks platelets, the cell fragments that help blood clot, so counts fall and bruising and bleeding become likelier. The strongest evidence is for romiplostim, a medicine, and trials found lasting platelet responses in 38% of adults without a spleen and 52% of children, versus 0% and 10% on placebo. Those results come from specific groups, so they may not apply to everyone.
Sources: PMID 27103127
- Updated
- How we grade
- 58 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 4
No supplement studies yetWe haven’t found supplement studies for Immune Thrombocytopenia. The medicines and peptides studied for it are listed below.
Prescription medicines and peptides studied, for context
Key findings
- Bleeding ReductionImproves (the measure goes down)
- Durable Platelet ResponseImproves (the measure goes up)
- Overall Platelet ResponseImproves (the measure goes up)
Safety notes in the studies
- Safe long-term with no increased thrombosis or malignancy risk.
Studies cited
58 studies from PubMed
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
- Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.
- Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
- Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.
- Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.
- Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.
- Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.
- Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.
- Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings.
- A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli.
- Survival and Hematologic Benefits of Romiplostim After Acute Radiation Exposure Supported FDA Approval Under the Animal Rule.
- Romiplostim use in pregnant women with immune thrombocytopenia.
- Romiplostim drug presence in pregnancy and lactation.
- Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database.
- Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia.
- Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.
- Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
- Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies.
- Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of a Romiplostim Biosimilar in Chronic Refractory Immune Thrombocytopenic Purpura (ITP) Patients.
- Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review.
- A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
- Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
- Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.
- Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP).
- Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.
- Romiplostim (Nplate(®)) as an effective radiation countermeasure to improve survival and platelet recovery in mice.
- Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description.
- Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial.
- Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.
- Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
- Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report.
- Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.
- Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
- Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
- Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis.
- Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study
- Romiplostim for management of chemotherapy-induced thrombocytopenia.
- Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
- Romiplostim-induced myelofibrosis.
- Romiplostim: a review of its use in immune thrombocytopenia.
- The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
- Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
- Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
- The development of romiplostim for patients with immune thrombocytopenia.
- Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)
- Romiplostim or standard of care in patients with immune thrombocytopenia
- Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
- Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
- Romiplostim management of immune thrombocytopenic purpura.
- Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
- Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
- Romiplostim in chronic immune thrombocytopenic purpura.
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
- AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP